Amaroq Therapeutics is a New Zealand-based biotechnology company focused on developing a new class of therapeutics that target lncRNA in cancer.
Long non-coding RNAs are a relatively recently discovered class of molecules often referred to as “dark matter” of the human genome. These naturally occurring molecules do not code for proteins but fulfill important regulatory functions in the cell that could be exploited as a new therapeutic approach for multiple indications. Amaroq’s research team has discovered lncRNA molecules that are highly expressed in cancer cells, and once removed, cancer cell growth slows. Amaroq Therapeutics is developing innovative therapeutics to target lncRNAs for cancer treatment.
Amaroq Therapeutics is funded by the Medical Research Commercialisation Fund, managed by life science venture capital firm Brandon Capital Partners, Otago Innovation Ltd, University of Otago, Cure Kids, and NZ Innovation Booster. The Company has been spun out of research from the University of Otago in Dunedin, New Zealand.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 15 Customs St W, Level 22,pwc Tower,new Zealand
- Industry
- Biotechnology
- Website
- https://amaroqtx.com/
- Keywords
- Wellington.
- HQ
- Auckland
Amaroq Therapeutics Questions
Amaroq Therapeutics's website is https://amaroqtx.com/
Amaroq Therapeutics's LinkedIn profile is https://nz.linkedin.com/company/amaroqtx
Amaroq Therapeutics has
6 employees.
View email and phone details for 6
employees at Amaroq Therapeutics.
Amaroq Therapeutics's industry is
Biotechnology
Amaroq Therapeutics's top competitors are
Biotech New Zealand,
Bioviros,
Fold Ai,
Scion,
Biofab,
Myneo Therapeutics,
Malaghan Institute Of Medical Research,
Bioora,
Otago Biochemistry,
New Zealand Pharmaceuticals Limited.
Amaroq Therapeutics's categories are Biotechnology
Amaroq Therapeutics's founding year is 2021
